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1. Introduction
Neuroblastoma (NB) is the most common pediatric extracranial solid tumor of childhood, and
45% of patients have high-risk tumors, nearly all of which are metastatic (stage 4) when
diagnosed [1]. Patients with neuroblastoma are risk stratified based on presenting factors
including age, stage and location of disease, and specific biologic molecular markers of the
tumor, including NMYC status and ploidy [1-3]. Treatment given is tailored to whether a
patient has low, intermediate or high-risk disease. The overall prognosis for those with high
risk or relapsed disease remains poor despite the standard therapies of surgery, radiation, and
high dose chemotherapy followed by stem cell rescue. Additionally, many patients who
survive suffer from complications related to their treatment. In this chapter, we review the
literature that provides a rationale for the use of novel targeted agents to improve the treatment
and survival while lessening toxicity of patients with neuroblastoma who have failed standard
therapies.
In particular, we focus our discussion on a few specific signaling pathways. The central role
of the phosphatidylinositol 3-kinase-Akt-phosphatase and tensin homolog (PI3K-Akt-PTEN)
axis and RAF-MEK-ERK as potential molecular targets to control downstream effectors of
coordinated cell division, tumor growth, angiogenesis, apoptosis, invasion and cellular
metabolism in the tumor and surrounding stromal compartments. The PI3K and RAF-MEK-
ERK pathways have also been implicated in modulating p53, the hypoxia-inducible factor 1
(HIF1α), mycN and others.
NMYC is known to play a role in the tumorigenesis of certain high-risk neuroblastoma tumors
and its control has many implications in targeting therapy. Additional pathways and targets
explored in this chapter are the RAS/Raf/MEK/ERK pathway, specific angiogenesis inhibitors
including VEGF, ALK 1 mutations and inhibitors, and control of apoptosis through caspase 8.
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We also discuss the idea of synthetic lethality and the concepts of sequential versus simulta‐
neous inhibition. We will discuss the emerging importance of genomic and metabolomic
profiling in tumor interrogation with therapeutic considerations.
We will review the literature supporting a role for cancer stem cells (CSCs) in the pathogenesis
of neuroblastoma and the signaling pathways that define the CSC phenotype. We discuss the
role targeted therapies in CSC related therapeutics and the adaptive responses that such cells
have when exposed to targeted therapeutic agents.
Lastly, the emerging role of immunotherapeutics into both standard and targeted therapies
for neuroblastoma is explored. This includes areas of T cell and macrophage infiltration of
tumors, interleukin and cytokine involvement, and anti-GD2 human and mouse monoclonal
antibodies.
2. PTEN and PI-3 kinase and mycN signaling as targets for NB therapeutics
— The intercept node hypothesis
The idea that some signaling pathways are more central to tumorigenesis than others was
suggested by our laboratory and others [4]. From connectivity map analysis, some signaling
proteins appear connected to a large number of upstream and downstream effector pathways.
These are considered central “intercept nodes” [4, 5] which provide coordinate control over
the output of a large number of cell surface receptor input. The specificity of signaling
downstream of such intercept nodes is generally fine tuned by more specialized signaling
effector proteins e.g. Rac2, HIF1α, NFκB or mycN which encode more specific signaling
content. Two such central pathways, PTEN-PI-3-AKT and Raf-MEK-ERK are critical for NB
survival, proliferation, invasion and angiogenesis in vivo [6-9]. A large number of small and
large pharmaceutical companies have developed small molecule inhibitors which block these
two pathways. Considering the importance of mycN amplification in the pathogenesis of NB,
and the role of PI-3K and MAP kinase in the GSK3β dependent regulation of mycN a number
of investigators have determined the efficacy of PI-3 kinase inhibitors in NB models [9]. Despite
evidence of efficacy no PI-3 kinase inhibitors have entered pediatric oncology clinical trials to
date. One pan PI-3 kinase inhibitor, SF1126 is slated to enter pediatric oncology Phase I clinical
trials in early 2013 [10]. Importantly, the tumor and stromal compartment share many of the
same signaling pathways to regulate the process of tumorigenesis in vivo.
3. Role of angiogenesis in tumorigenicity of neuroblastoma / PI3 kinase
and VEGF inhibitors in treatment of neuroblastoma
Work from a number of laboratories indicates that the angiogenic response is coordinately and
highly regulated physiologic response to hypoxia and inflammation. Hence it is not surprising
to learn that central node in mammalian cells control output from many cell surface receptors
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to regulate this response [11]. We and others have shown that PTEN a major tumor suppressor
protein regulates angiogenesis and loss of PTEN results in deregulation of PTEN and multiple
downstream signaling pathways shown in Fig. 1 and 2 which have all been implicated in the
literature to exert coordinate control of angiogenesis in vivo [4, 5, 12, 13].
In general, angiogenesis plays an important role in the progression and metastasis of malignant
tumors [14]. In neuroblastoma, tumor vascularity is correlated with an aggressive phenotype
[15, 16]. Pro-angiogenic factors are differentially expressed in high-risk neuroblastoma [17,
18]. Vascular endothelial growth factor (VEGF) is a specific endothelial cell mitogen that
stimulates angiogenesis and plays a crucial role in tumor growth [19]. Over expression of VEGF
has been demonstrated in neuroblastoma, nephroblastoma, as well as in various other cancers
[20-22]. Recent studies have validated inhibition of VEGF as an effective antiangiogenic
therapy in some of these cancers [23-25]. Although several preliminary studies have demon‐
strated that expression of angiogenic growth factors, including VEGF, correlate with a high-
risk phenotype in neuroblastoma, clinical data are still insufficient to draw conclusions [17, 21,
26, 27]. Therefore, further clinical studies, are needed to evaluate the possible significance of
these factors for use in a routine clinical practice. Preclinical studies also suggest that antian‐
giogenic strategies may be effective in the treatment of neuroblastoma [28]. In addition, phase
I clinical trials (COG study) using the human anti-VEGF antibody, bevacizumab, in pediatric
patients with refractory solid tumors reported promising results [29]. Recently, Jakovljevic et
al. has determined VEGF expression by immunohistochemistry using antiVEGF antibody in
Figure 1. The PI3K–Akt–PTEN intercept node. As shown, a large number of growth factor receptors (GFR) of which
TrkB is an oncogene in NB would feed into the central node to activate PI-3 kinase, AKT and/or Raf-MEK-ERK path‐
ways. Downstream subnodes encode specificity e.g. GSK3b, MDM2, mycN, Rac2, etc. Major tumor suppressors like
PTEN and p53 control output from these two central nodes. MDM2 regulates p53 in an AKT dependent manner; RAF-
MEK-ERK and AKT regulate GSK3b to control mycN stabilitity and transcriptional activity.
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paraffin embedded primary tumor tissue from 56 neuroblastoma patients and reported that
VEGF expression correlated with disease stage and survival in neuroblastoma patients [30].
Whether inhibition of angiogenesis is a realistic approach for preventing dissemination of
neuroblastoma remains to be determined, but we can suggest that inhibitors of VEGF can be
used in the treatment of neuroblastoma. Finally, we suggest that the more global inhibition of
PI3 kinase or combined PI3K/MEK inhibition would provide a more potent antiangiogenic
modality to block tumor induced angiogenesis in this disease.
4. Cancer stem cells in neuroblastoma tumorigenicity
The Cancer Stem Cell Theory postulates that tumors contain a subset of cells that are capable
of increased self-renewal and differentiation, can propagate tumor growth and are resistant
to apoptosis [31, 32]. These stem-like cancer cells are analogous to normal stem cells [33] but
differentiate into diverse cancer cells that form the major portion of the tumor. Recent evidence
suggests the presence of stem cells in various cancers including those of the blood [34], breast
[35], prostrate [36] and brain [37].
Evidence for the presence of cancer stem cells in brain tumors first came from the observation
that human medulloblastoma, astrocytomas, and ependymomas contain cells that express the
neural stem cell marker CD133 [38] [39]. Singh et al. [37] have shown that human brain tumors
contain CD133+ stem-like cells that are capable of growing tumors in immune-deficient mice.
Cournoyer et al.[40] have shown that CD133 high neuroblastoma (NB) cells have high tumor
initiating cell properties, and Coulon et al.[41] suggest that CD133, ABC transporter, Wnt and
NOTCH genes are sphere markers in NB cells. Overall, 19–29 % of cells in glioblastomas and
6–21 % of cells of medulloblastomas are reported to be CD133+ and tumorigenic [33]. Recently,
several groups have suggested that CD15 (stage specific embryonic antigen 1 or SSEA-1),
which is expressed on neural progenitor and stem cells, may be a better marker than CD133
of tumor-initiating cells in MB, glioma, and ependymoma [42-44]. Hansford et al has recently
identified tumor initiating cells from NB bone marrow metastases that have several properties
of cancer stem cells including the expression of stem cell markers, the ability to self renew and
the capability to form metastatic NB in immunodeficient animals with as few as 10 cells [45].
Kaplan’s laboratory has further defined the NB tumor initiating cell (TIC) with stem cell like
properties to express, CD133 and CD44. These cells isolated from NB bone marrow have tumor
initiating activity and upon profiling display sensitivity to a number of targeted therapeutic
agents.
A key aspect of the tumor stem cell (TSC) niche is the balance of signals received, and over
recent years considerable attention has been directed towards understanding the role of
signaling pathways, which are critical mediators of normal stem cell biology, in cancers. The
embryonic signaling pathways most commonly implicated in tumorigenesis include Hedge‐
hog, Notch, and Wnt pathways. Sonic Hedgehog (SHH) signaling is important in embryonic
cell development and proliferation and aberrant pathway activation can lead to tumor
formation, tumor cell self-renewal and the development of metastatic disease [48].Similarly,
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Notch plays a crucial role in biological functions of development and cell fate including cell
differentiation and proliferation [49]. Constitutive activation of Notch can lead to tumorigen‐
esis and cell survival, and Notch activity is involved in tumor angiogenesis [50]. The Wnt
Figure 2. Signaling and cellular pathways controlling tumorigenicity of Neuroblastoma. In tumor compartment
PI3K–Akt–PTEN intercept node is a central regulator of survival, proliferation, invasion and angiogenesis in Neuroblas‐
toma. PI3K controls PIP3 levels, thereby regulating lipid-associated second messenger output from upstream effectors.
PI3K and Akt can be activated by many cell surface receptors. Akt becomes locked in an active conformation and
phosphorylates numerous proteins involved in growth and survival, cellular metabolism, stress response and angio‐
genesis. Akt modulates phosphorylation of GSK3β and relieves tonic inhibition of c-Myc and cyclin D to promote cell
survival [46]. Akt contributes to the Warburg effect by inducing HIF1α transcription and stimulating aerobic glycolysis.
Intratumoral hypoxia also drives angiogenesis through transcription of proangiogenic genes including VEGF and
PDGF. Tumor angiogenesis is promoted by Akt-mediated phosphorylation of MDM2. Activated MDM2 translocates
from the cytoplasm to the nucleus, where it binds p53, targeting it for ubiquitination and degradation. This process
prevents p53 from exerting its antiangiogenic effect. A more effective strategy might be to modulate tumor growth
and angiogenesis by targeting major signaling nodes such as the p53–MDM2 or PI3K–Akt–PTEN nodes with agents
such as Nutlin 3A or with PI3K inhibitors (e.g. PI-103, BEZ-235 or SF1126), respectively. Abbreviations: GSK3β, glycogen
synthase kinase 3 β; HIF1α, hypoxia inducible factor 1α; MDM2, mammalian double minute 2; PDGF, platelet-derived
growth factor; PI3K, phosphatidylinositol 3-kinase; In stromal compartment, the major cellular pathways of the im‐
mune response which may have anti- or pro-tumor effects are shown. NK cells and CD8+ CTLs may directly target tu‐
mor cells for lysis; however this may be countered by decreased tumor expression of NKG2D ligands or MHC class I.
Dendritic cells are important for priming an anti-tumor immune response, although immature DCs and IDO-express‐
ing DCs may instead lead to the induction of tolerance. Myeloid-derived suppressor cells and regulatory T cells (Treg)
may also suppress the anti-tumor CTL response. TH1 cells and M1 macrophages produce proinflammatory cytokines
which help to stimulate the anti-tumor immune response, whilst TH2 cells (and other cell types) produce IL-10 which
may have a predominantly inhibitory effect on the anti-tumor response. Tumor-associated M2 macrophages may pro‐
mote tumor growth and metastases via a number of different mechanisms. Figure adopted from Morgenstern et al
[47].
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family proteins help direct a wide range of developmental processes including cell fate,
proliferation, motility, and polarity [51]. Dysregulation of the Wnt pathways has been
implicated in tumor formation, proliferation, and maintenance [52]. All of the current pediatric
studies demonstrating that progenitor and stem cells can respond to embryonic signaling have
been in MB or primitive neuroectodermal tumors (PNET). Aberrant SHH signaling has been
implicated in MB, and recently was used to define one of four distinct molecular variants of
MB [53].
In order to identify pathways required for proliferation and cell survival characteristics of TIC
in neuroblastoma, Grinshtein et al. has performed drug screen on bone marrow derived tumor
initiating cells (TICs) with a unique collection of pharmacological inhibitors. They identified
that PI3K (phosphoinositide 3 kinase)/AKT, PKC (protein kinase C), Aurora, ErbB2, Trk and
Polo-like kinase 1 (PLK1) are the potential kinase targets for survival of TIC [54]. Their studies
demonstrated that PLK1 inhibitors are an attractive candidate therapy for metastatic NB.
Another group suggested that both PI-3 kinase as well as Ras-RAF-MEK-Erk signaling
pathways promote the tumorigenicity of the glioblastoma cancer stem like cells, and combined
treatment with MEK and PI-3 kinase inhibitors can block the differentiation of glioblastoma
cancer stem like cell into non tumor initiating status [55].
The therapeutic resistance of cancer stem cell to current treatment modalities such as chemo‐
therapy and radiation make these cells clinically relevant irrespective of their origin. Resistance
to chemotherapeutic agents has been demonstrated in neuroblastoma stem cells and sarcoma
stem cells including Ewing’s sarcoma and osteosarcoma. Recent work by Hambardzumyan
suggests that the PI-3 kinase pathway activity promotes post-radiation survival in cancer stem
cells in medulloblastoma [67]. Although lots of literatures are available on the cancer stem cell
in neuroblastoma but yet the novel signaling pathways controlling the proliferation and
survival of cancer stem cell and the mechanism behind resistance developed due to chemo‐
therapy needs to be investigated.
5. Neuroblastoma and cancer metabolism
It has been known from a long time that cancer cells take up and metabolize glucose and
glutamine to a degree that far exceeds their needs for these molecules in anabolic macromo‐
lecular synthesis [56]. Commonly occurring oncogenic signal transduction pathways initiated
by receptor tyrosine kinases or Ras engage PI3K-Akt signaling to directly stimulate glycolytic
metabolism under aerobic conditions a condition termed the Warburg and Pasteur effects
[56-58]. Myc-activation/amplification is one of the most common oncogenic events observed
in cancer and is known to drive the progression of a certain subgroup of neuroblastoma [59].
The activation of mycN could occur through amplification of the mycN gene or through
upstream activation of signaling pathways that would stabilize mycN e.g. trkB, IGF-1 or the
activation of Raf and/or PI-3K-AKT stimulation. Oncogenic levels of Myc have recently been
linked to increased glutaminolysis through a coordinated transcriptional program program
[60-62]. Quantitative RTPCR and ChIP experiments support Myc’s binding and transcriptional
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activation of two high affinity glutamine transporters: SLC38A5 (also called SN2) and SLC1A5
(ASCT2), the transporter required for glutamine-dependent mTORC1 activation [60, 63]. In
addition to facilitating glutamine uptake, Myc promotes the metabolism of imported gluta‐
mine into glutamic acid and ultimately into lactic acid [60]. Whether the tendency of Myc to
complement Ras and PI3K-Akt [64, 65] is related to the interdependence of glutamine and
glucose metabolism in support of cell growth remains an open question. The work of C. Dang
and other points to a potential important metabolic requirement for glutamine in c-myc and
mycN driven tumors where glutamine can serve a role in promoting tumor growth [58, 66].
This might suggest a role of agents which deplete glutamine (glutaminases) as a therapeutic
target for mycN driven malignancies like neuroblastoma and the SHH subtype of medullo‐
blastoma.
6. Role of tumor infiltrating immune cells in tumorigenicity of
neuroblastoma
Solid tumors are composed of tumor stromal cells, blood vessels, infiltrating immune cells and
tumor cells themselves. Over the last decade, a growing body of literature has highlighted the
importance of the tumor microenvironment for the prognosis of different types of cancer [68].
The tumor microenvironment contains many resident cell types, such as adipocytes and
fibroblasts, but it is also populated by migratory hematopoietic cells, including lymphoid cells,
granulocytes, mast cells, dendritic cells, natural killer cells, neutrophils and macrophages.
These haematopoietic cells have pivotal roles in the progression and metastasis of tumors [69,
70]. The significance of tumor stroma for the overall prognosis may be in part due to the fact
that several components of the tumor-microenvironment have been shown to compromise
immune effect functions against tumor cells [71]. The concept of tumor-promoting inflamma‐
tion is a recognized enabling characteristic of cancers [72].
The first evidence suggesting immune responses to neuroblastoma was provided in 1968 when
blood leukocytes, which were 50–70% lymphocytes, were reported to inhibit colony formation
by neuroblastoma cells [73]. These lymphocytes inhibited colony formation by both autologous
and allogeneic neuroblastoma cells but did not affect growth of fibroblasts from the same
donors. Plasma from these patients also was reported to inhibit tumor cell colony formation
in the presence of complement. In this same time, primary tumors were reported to contain
leukocytes [74, 75], and some localized and metastatic neuroblastomas were reported to regress
spontaneously [76, 77]. Together, these studies suggest that the immune system could develop
an anti-neuroblastoma response. In this section, we will highlight the role of tumor infiltrating
immune cells in progression of this disease and how blocking the function of these infiltrating
cells may prove beneficial in its treatment of NB.
a. Tumor infiltrating Lymphocytes
Tumor-associated lymphocyte population includes CD8+ cytotoxic T cells, CD4+ T helper cells,
regulatory T cells (Tregs), NKT or γδT cells. Tregs are immunosuppressive regulatory T cells.
Tregs are able to suppress the activity of CTLs by direct cell-cell contact and also secrete
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immunoregulatory cytokines such as transforming growth factor β (TGF-β) and interleukin-10
(IL-10). However, the role of Tregs is much less clear and to our knowledge there are no
published data on the presence (or otherwise) of Tregs in pediatric tumors.
CD8+ cytotoxic T lymphocytes (CTL) are a primary source of anti-tumor activity in the immune
system [1, 3]. In many adult cancers the presence of significant numbers of tumor-infiltrating
lymphocytes, potentially represents the host immune response against the tumor and is
associated with improved prognosis [78-80]. In neuroblastoma, Martin et al. [81] suggested a
correlation between lymphocyte infiltration and improved survival, although these data are
confounded by tumor grade since lymphocytic infiltrates were seen more frequently in low
grade, differentiating tumors. In a separate examination of 26 high-risk neuroblastoma tumor
samples, there was minimal or undetectable infiltration of CD8+ or CD4+ T cells, CD20+ B cells
or CD56+ NK cells within tumor nests [82], although in most patients CD8+ or CD4+ lympho‐
cytes were present within the peritumoral stroma. Interestingly, the majority of patients had
evidence of small numbers of circulating cytotoxic T cells against the tumor antigen survivin
(expressed by all of the tumors in this study) and these CTLs were highly functional in in
vitro assays [82]. The experiments conducted by another group in NXS2 murine neuroblastoma
model have shown that oral vaccination with a survivin DNA minigene was associated with
increased target cell lysis, increased presence of CD8(+) T-cells at the primary tumor site, and
enhanced production of pro-inflammatory cytokines [83]. Another pre-clinical study have
demonstrated that tyrosine hydroxylase and MYCN proteins, which are relatively specific for
neuroblastoma cells compared to normal cells, include peptides that can be targets for CTL.
Vaccination of mice with tyrosine hydroxylase DNA minigenes can induce CTLs, eradicate
established primary NXS2 neuroblastoma tumors, and inhibit spontaneous metastases
without induction of autoimmunity [84, 85].
However, despite these cellular responses to NB, the presence of tumor-infiltrating CTL is rare,
suggesting a block in T cell trafficking that may protect the tumor from CTL-mediated
cytotoxicity. Therefore, strategies aiming to generate CTLs must take into account mechanisms
by which neuroblastoma cells may avoid immune elimination. These include decreased
expression of peptide presenting HLA class I molecules by tumor cells, which can impair target
peptide recognition by CTLs [82, 86, 87]. Also, neuroblastoma cells express low levels of
antigen processing genes, including LMP-2, LMP-7, and TAP-1, which are necessary for
preparation of peptides from proteins for presentation by HLA class I molecules to CTLs [88,
89]. Neuroblastoma cells also induce monocytes to release HLA-G, which suppresses both CTL
and NK mediated cytotoxicity by interacting with inhibitory receptors or inducing apoptosis
via CD8 ligation or the Fas-FasL pathway [90]. Thus, effective CTL anti-tumor responses
require that these escape mechanisms be evaluated and, if present, be overcome.
b. Natural Killer Cells
Natural Killer (NK) cells represent a particular subset of T lymphocytes, which express both
T cell markers, such as the αβ T-cell receptor (TCR) and associated CD3 complex, and NK cell
markers, such as NK1.1[91]. These cells recognize glycolipids presented by the MHC class I-
like molecule CD1d and are believed to play an important role at the interface between the
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innate and adaptive immune responses to infection and malignancy [92]. Two main subtypes
of NKT cell are recognised, with Type I NKT cells expressing an invariant α-TCR chain and
being implicated in antitumor immunity, whilst Type II NKT cells express a variety of TCR
molecules (in addition to CD1d) and appear to have a more immune inhibitory role [91]. The
presence of these immune effector cells within tumors has been examined in a number of
different malignancies, including, neuroblastoma. Type I NKT cells were found in 53% of 98
untreated primary stage 4 neuroblastoma samples [93] and their infiltration correlated with
favorable outcome, with expression of the chemokine CCL2 and with absence of MYCN
amplification (indicating less aggressive disease). Subsequent investigations have confirmed
that expression of CCL2 is repressed in MYCN amplified tumors, leading to a failure of NKT
cell infiltration and potentially contributing to tumor immune escape [94].
Recent studies have suggested anti-tumor role of NK cells in high risk neuroblastoma NK cells
are activated to be cytotoxic and secrete IFNγ by IL-2. IL-2 alone has been tested in phase I and
II trials for patients with neuroblastoma, and, although immune effects were documented, no
objective tumor responses were observed [95, 96]. Lenalidomide is an immune modulating
drug that activates T cells to secrete IL-2, which in turn activates NK cell cytotoxicity and ADCC
[97, 98]. Clinical trials in children and adults demonstrated increased numbers of NK cells and
cytotoxicity, decreased T regulatory cells, and increased secretion of IL-2, IL-15, and GM-CSF
after 21 days of lenalidomide treatment [99, 100]. Thus, lenalidomide may be useful for
activating NK cells to enhance mAb immunotherapy of neuroblastoma.
c. Role of tumor associated macrophages
Macrophages represent a further important cellular component of the tumor stroma. Far from
being mere bystanders to tumor development, there is increasing evidence that tumor-
associated macrophages (TAMs) promote and facilitate tumor growth [101, 102]. Of key
importance is the concept of distinct macrophage phenotypes, mirroring the dichotomy
between TH1 and TH2 T helper cells and type I and type II immune responses. Alternatively
activated M2-macrophages are involved in polarized Th2 inflammatory reactions and
characterized by expression of arginase-1 and mannose and scavenger receptors [103, 104]. On
the other extreme, classically activated M1 macrophages are IL-12 high, IL-23 high, IL-10 low;
produce high levels of inducible nitric oxide synthetase (iNOS); secrete inflammatory cyto‐
kines such as IL-1β, IL-6, and TNF; and are inducer and effector cells in Th1 type inflammatory
responses [105]. It has been suggested that tumor-associated macrophages (TAMs) display an
M2-like phenotype [106].
TAMs are recruited to tumors when stimulated by growth factors and chemokines, produced
by the tumor cells [107, 108]. The conventional wisdom about TAM function is that they are
recruited to reject the tumor, which has been recognized as foreign because tumors express
unique antigens. However, there is a growing body of evidence that the tumor microenviron‐
ment is immunosuppressive [109], perhaps as a result of selection for such an environment a
process recently termed ‘immunoediting. Recent data indicate that TGF-β1 has an important
role in suppressing these local responses and that inhibiting this molecule can result in tumor
rejection [110, 111]. It is noteworthy that TAMs can both produce TGF-β1 and process latent
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TGF-βs to produce their active forms[111]. In addition, the local cytokine milieu in the tumor
tends to block the immunological functions of these newly recruited mononuclear phagocytes
such as antigen presentation and cytotoxicity towards tumors, and diverts them towards
specialized TAMs that are immunosuppressed and trophic [112]. A principal component of
this cytokine mixture is CSF-1, which locally blocks the maturation of dendritic cells so that
they are unable to present antigens and promotes the development of immunosuppressed
trophic TAMs. TAMs promote tumor growth by affecting angiogenesis, immune suppression,
invasion and metastasis [101, 102]. Existing literature suggests that tumor associated macro‐
phages secrete several genes including matrix metalloproteinases-9 (MMP-9) [113], urokinase-
type plasminogen activator (uPA) [114], vascular endothelial growth factor (VEGF) [115], and
cyclooxygenase-2 (Cox-2] [116] which promotes tumor growth by breaking down extracellular
matrix. The role of TAMs in tumor growth and progression is highlighted in Figure 3.
Figure 3. The role of TAMs in tumor growth, invasion and metastasis: Tumor-derived chemokines, cytokines and vascu‐
lar endothelial growth factor (VEGF), actively recruit circulating blood monocytes at the tumor site In the tumor micro-envi‐
ronment monocytes differentiate into tumor-associated macrophages (TAM), where they promote tumor growth and
metastasis and establish a symbiotic relationship with tumor cells. The above tumor-derived factors positively modulate
TAM survival. TAMs also secrete growth factors, which promote tumor cell proliferation and survival, regulate matrix depo‐
sition and remodeling and activate neo-angiogenesis. Figure modified and adapted from Sica et al. [106]
Clinical studies have, on balance, shown a correlation between an abundance of TAMs and
poor prognosis [108]. These data are particularly strong for breast, prostate, pancreatic, ovarian
and cervical cancers; the data for stomach and lung cancers are contradictory [108, 117, 118],
and in a small study in colorectal cancer, their presence was associated with good prognosis
[119]. However, taking all reports into account regardless of method and sample number more
than 80% show a significant correlation between TAM density and poor prognosis, whereas
less than 10% associate TAM density with a good prognosis [108]. So, increased TAM density
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is usually associated with advanced tumor progression and metastasis in most of the cancers.
However the prognostic significance of tumor associated inflammatory cells in metastatic
disease and in childhood cancers is mostly unknown.
Recent reports suggest that interaction between tumor and inflammatory cells contribute to the
clinical metastatic neuroblastoma phenotype [120]. It has been reported that metastatic neuro‐
blastomas had higher infiltration of TAMs than loco regional tumors, and metastatic tumors
diagnosed in patients at age ≥ 18 months had higher expression of inflammation related genes
than those in patients diagnosed at age < 18 months. They identified 14 genes, out of which nine
were tumor cell related and five were inflammation related that comprises a prognostic signature
for neuroblastoma. Expression of inflammation related genes representing TAMs (CD33/CD16/
IL6R/IL10/FCGR3) contributed to 25% of the accuracy of a novel 14-gene tumor classification
score [120]. Another study by Song et al., demonstrated that CD1d+ TAMs promote neuroblasto‐
ma growth via IL-6 production and that expression of monocyte/macrophage markers, CD14/
CD16, and IL-6 or IL-6R inversely correlates with long-term disease-free survival in patients with
stage 4 MYCN–non-amplified neuroblastoma [121]. They suggested that cotransfer of human
monocytes and NKTs to tumor-bearing NOD/SCID mice decreased monocyte number at the
tumor site and suppressed tumor growth compared with mice transferred with monocytes alone.
Thus killing of TAMs can be suggested as a novel mechanism of NKT antitumor activity that
relates to the disease outcome. Although less is known about the role of stromal compartment in
tumorigenecity in neuroblastoma and other childhood tumors but recent reports suggesting
infiltration of macrophages in metastatic neuroblastoma opened new opportunities to target
tumor associated immune system cells in childhood cancer. It is unclear whether these TAMs
represent M2 macrophages and the mechanisms that control macrophage differentiation along
the M1 vs the M2 lineage in tumor biology.
7. Multiple ‘Omics’ analysis an emerging concept in treatment of
neuroblastoma
The “Omics” is a neologism widely adopted by scientists to refer to large scale analysis of genes
(genomic), proteins (proteomics) and lately small metabolites (metabolomics). Modern molecu‐
lar achievements over the last decade have seen the increase and implementation of multiple
'omics technologies in oncology that promises to provide for a deeper comprehension of complex
tumor pathways. It is believed that an integration of multiple “omics” technologies is likely to
provide even further insight into the holistic view of the biology networks [122]. The studies of
global expression profiles of both mRNA and protein are necessary to reveal the important
pathways for an enigmatic disease such as neuroblastoma. During the past several years many
studies utilized microarray-based high throughput technologies to investigate gene expres‐
sion profiles and DNA copy number alterations in neuroblastoma [123, 124]. Guo et al. has
performed exon array profiling to investigate global alternative splicing pattern of 47 neuroblas‐
toma samples in stage 1 and stage 4 with normal or amplified MYCN copy number (stage 1-, 4-
and 4+) Their results demonstrated a significant role of alternative splicing in high stage
neuroblastoma and suggested a MYCN-associated splicing regulation pathway in stage 4+
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tumors [125]. Studies from other group has measured copy number alterations in a representa‐
tive set of 82 diagnostic tumors on a customized high-resolution BAC array based CGH platform
supplemented with additional clones across 1p36, 2p24, 3p21-22, 11q14-24, and 16p12-13, and
integrated these data with RNA expression data[126]. They used an unbiased statistical method
to define a set of minimal common regions (MCRs) of aberration and on the basis of unsuper‐
vised hierarchal clustering they identified four distinct genomic subclasses. These genomic
subsets were highly correlated with patient outcome, and individual MCRs remained prognos‐
tic in a multivariable model. These studies mentioned above identified prognostic markers and
genomic alterations specific to high-risk neuroblastoma, and showed the capability of identify‐
ing signatures which predict patient outcome. Since mRNA expression is not always indica‐
tive of corresponding protein expression because the abundance of specific proteins can be
controlled by post-transcriptional translation and post-translational modifications, therefore the
use of proteomics will help in detecting directly the actual biological effector molecules and
should provide more accurate functional information about biological systems. With this idea,
Chen et al. has performed parallel global protein and mRNA expression profiling on NB tumors
of stage4 MYCN-amplified (4+) and stage1 MYCN-not-amplified (1-) using isotope-coded
affinity tags (ICAT) and Affymetrix U133plus2 microarray respectively [127]. Pathway analy‐
sis of the differentially expressed proteins conducted by this group showed the enrichment of
glycolysis, DNA replication and cell cycle processes in the upregulated proteins and cell
adhesion, nervous system development and cell differentiation processes in the down-regulat‐
ed proteins in 4+ tumors; suggesting a less mature neural and a more invasive phenotype of 4+
tumor.
Metabolomics falls behind its predecessor genomics and proteomics, but represent a burgeon‐
ing field with potential to fill up the gap between genotype and phenotype [128] The high
throughput nature of metabolomics makes it an attractive tool for scientists involved in the
process of drug development. The reason for that lies in the principle that a patients response
to drugs and toxicities do not depend only on a person genetic make-up, but it is rather a
factorial outcome of interactions between intrinsic factors and environment [128]. Therefore,
metabolomics technology is a powerful tool that can accurately measure the entire spectrum
of biochemical changes and mapping these changes to metabolic pathways [128, 129]. In 1995,
Florian et al. [130] determined the metabolic characteristics of three types of human brain and
nervous system tumors by high-resolution in vitro MRS and chromatographic analysis. Signals
from leucine, isoleucine, glycine, valine, threonine, lactate, acetate, glutamate, and choline-
containing compounds were similarly detected in meningiomas, glioblastomas, and NB. In
2007, Peet et al. [131] reported the results of in vitro 1H high-resolution magic angle spinning
NMR spectroscopy (HRMAS) investigations performed on cell suspension of 13 lines of NB
possessing multiple genetic alterations. In their study, a specific metabolite profile associated
with MYCN-amplified and non-amplified tumor subtypes was described. Phosphocholine and
taurine concentration ratios relative to total choline were found to be significantly more
elevated in the MYCN-amplified as compared to the MYCN-non-amplified cell lines, and
suggested that choline and taurine molecular pathways could be potential therapeutic targets
in NB[131]. Recently, Imperiale et al. has characterized the metabolic content of intact biopsy
samples obtained from 12 patients suffering from neuroblastoma by using (HRMAS) [132].
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Their studies suggested that NB patients younger than 12 months contained a higher level of
acetate and lysine. Conversely, higher amounts of glutathione, glutamate, myoinositol glycine,
serine and ascorbic acid were detected in NB samples belonging to younger children.
Overall, the emerging concept of analyzing NB-specific 'omics profiles to better understand
and define the behavior of advanced-stage tumors along with providing direct and targeted
therapy may ultimately translate into improved outcomes for high-risk NB.
8. Antibody dependent cellular toxicity (ADCC) / Role of ITAM and ITIM
signaling in neuroblastoma
The Fcγ receptors (FcγRs) expressed on hematopoietic cells play a key role in immune defenses
by linking humoral and cellular immunity [133]. FcγRs display coordinate and opposing roles
in immune responses depending on their cytoplasmic region and/or their associated chains.
Indeed, the activating receptors contain an immunoreceptor tyrosine-based activation motif
(ITAM) and initiate inflammatory, cytolytic, and phagocytic activities of immune effector cells.
In contrast, the inhibitory receptors that downmodulate the immune responses contain an
immunoreceptor tyrosine-based inhibitory motif (ITIM) [134, 135]. There are numerous Fc
receptors for IgG (FcγR) that are widely expressed on immune cells. The FcγR family consists
of four classes of receptors, FcγRI, FcγRII, FcγRIII, and FcγRIV, that have been identified in
both mice and humans. There are significant similarities in the functions of the FcγR receptors
between mice and humans, but there is limited homology in receptors themselves [136]. To
date, only one inhibitory FcγR, FcγRIIb, has been identified and is the only receptor to have
complete homology between mice and humans [136]. FcγRs can be found on virtually all
hematopoietic cells except T cells; in most cases, cells coexpress activating and inhibitory FcγR,
allowing for the balance between activating and inhibitory receptors to dictate their response
[136]. NK cells are an exception to this rule and express only the activating FcγRIIIa. NK cells
do not express the inhibitory FcγRIIb.
Antibodies directed against neoplastic cells provide new therapeutic approaches against various
malignancies, including lymphoma, leukemia, melanoma, and breast and colorectal carcino‐
ma [137, 138] There is increasing evidence that the Fc portion of the anti-tumor IgG is a major
component of their therapeutic activity, along with other mechanisms such as activation of
apoptosis, blockade of signaling pathways, or masking of tumor antigens. Thus, by binding to
activating  FcγRs  expressed  by  immune  effector  cells,  such  as  macrophages,  monocytes,
neutrophils, or NK cells, tumor-specific antibodies trigger the destruction of malignant cells via
antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis [139, 140].
Because of their rapid and unopposed responses to mAb, NK cells play a major role in the anti-
tumor response elicited by tumor-specific mAbs. Multiple clinically successful mAbs utilize
NK-mediated ADCC as a mechanism of action. Rituximab (anti-CD20), Herceptin (anti-Her-2/
neu), Cetuximab (anti-EGFR), and the anti-GD2-mAbs 3F8 and ch14.18 are examples of tumor-
specific mAbs whose clinical activity can be attributed, at least in part, to NK cells. Natural
killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through
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tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been
successfully applied in the clinic and are included in the standard of care for certain malig‐
nancies. Strategies to augment the antitumor response by NK cells have led to an increased
understanding of how to improve their effector responses. Next-generation reagents, such as
molecularly modified mAbs and mAb-cytokine fusion proteins (immunocytokines, ICs)
designed to augment NK-mediated killing, are showing promise in preclinical and some
clinical settings. Continued research into the antitumor effects induced by NK cells and tumor-
targeted mAbs suggests that additional intrinsic and extrinsic factors may influence the
antitumor response. Therefore more research is needed that focuses on evaluating which NK
cell and tumor criteria are best predictive of a clinical response and which combination
immunotherapy regimens to pursue for distinct clinical settings.
9. Tumor associated gangliosides / GD2 monoclonal antibodies
Gangliosides (GD) are membrane-associated glycosphingolipids which have important
regulatory roles during embryogenesis and have also been implicated in tumor development.
Particular gangliosides, which show restricted patterns of expression in normal tissue, may be
expressed at high levels by tumor cells (e.g. GD3 by melanoma) and are implicated both in
tumorigenesis and as mediators of metastatic spread [141]. There is also evidence that
gangliosides secreted by tumor cells can modulate the immune response and, in particular,
act to inhibit dendritic cell differentiation and function. Neuroblastoma (and other neuroen‐
docrine) tumor cells ubiquitously express the ganglioside GD2, whilst expression in normal
tissues is restricted to neurons. Thus, GD2 is an attractive antigen for neuroblastoma immu‐
notherapy strategies [142] including humanized anti-GD2 monoclonal antibodies such as
ch14.18 [143], or GD2-directed cytotoxic lymphocytes. A chimeric human–murine anti-GD2
monoclonal antibody [144] called ch14.18 has shown activity against neuroblastoma in
preclinical studies [145] and early-phase clinicaltrials[146, 147], this activity could be enhanced
when ch14.18 is used in combination with granulocyte–macrophage colony-stimulating factor
(GM-CSF) [148] or interleukin-2 [149, 150] to augment antibody-dependent cell-mediated
cytotoxicity. The feasibility of administering ch14.18 in combination with GM-CSF, interleu‐
kin-2, and isotretinoin during the early post-transplantation period has been shown in two
sequential pilot phase 1 studies [143, 151]. This progression of clinical trials culminated in the
recently completed phase III randomized study of isotretinoin together with ch14.18, IL-2, and
GMCSF vs. isotretinoin only for children with high-risk neuroblastoma who had a clinical
response to induction therapy and myeloablative consolidation therapy/AHSCT. Immuno‐
therapy after consolidation significantly improve event free survival (EFS) (66 ±5% vs. 46 ±5%
at 2 years, P = 0.01) and overall survival (86 ± 4% vs. 75 ± 5% at 2 years, P = 0.02). This was the
first demonstration that antibody based therapy improves EFS and overall survival. Although
EFS was improved by adding immunotherapy to isotretinoin, approximately 40% of patients
still relapsed during or after this therapy [152]. Additionally, the combination of ch14.18 with
IL-2 and GM-CSF has significant toxicities, including neuropathic pain, fever without neutro‐
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penia, infection, hypokalemia, hypotension, and capillary leak syndrome. Thus, a search for
new agents to combine with ch14.18 to improve efficacy and decrease toxicity is justified.
Immunocytokines commonly known as antibody-cytokine fusion proteins combine the
targeting ability of antibodies with the functional activity of cytokines, and are known to
improve antibody-based therapy by delivering cytokines to the microenvironment to both
activate effector cells and modulate the microenvironment. To date, immunocytokine research
has focused on ADCC mediated by NK cells and on induction of CTL. An anti-GD2/IL-2
immunocytokine eradicated hepatic metastases of neuroblastomas in SCID mice that had been
reconstituted with human lymphokine (IL-2) activated killer cells [153, 154]. In contrast, the
combination of monoclonal anti-GD2 antibody and IL-2 at doses equivalent to the immuno‐
cytokine only reduced tumor load. In a syngeneic murine model of GD2 expressing melanoma,
targeting with an anti-GD2 antibody/IL-2 immunocytokine resulted in generation of CD8+ T
lymphocytes that could eradicate tumor as well as prevent tumor growth [154]. Based upon
these data, phase I and II studies have tested a humanized anti-GD2/IL-2 immunocytokine
(hu14.18/IL-2) in patients with refractory or relapsed neuroblastoma. In the phase I study of
27 patients, treatment with hu14.18/IL2 caused elevated serum levels of soluble IL-2 receptor
alpha (sIL2R_) and lymphocytosis. There were no measurable complete or partial responses
to hu14.18/IL2; however, three patients showed evidence of antitumor activity [155]. In the
phase II study, 39 patients with recurrent or refractory neuroblastoma were enrolled (36
evaluable). No responses were seen for patients with disease measurable by standard radio‐
graphic criteria (stratum 1) (n = 13). Of 23 patients with disease evaluable only by 123I-
metaiodobenzylguanidine (MIBG) scintigraphy and/or bone marrow histology (stratum 2),
five patients (21.7%) responded; all had a complete response of 9, 13, 20, 30, and 35+ months
duration. Grade 3 and 4 non-hematologic toxicities included capillary leak, hypoxia, pain, rash,
allergic reaction, elevated transaminases, and hyperbilirubinemia, which were reversible
within a few days of completing a treatment course. These results support further testing of
hu14.18/IL2 in children with non-bulky high-risk neuroblastoma [156].
10. Summary
Herein, we have reviewed a number of important areas of basic and translational research
related to emerging novel therapies for the pediatric solid tumor, neuroblastoma. These
include: 1) Signaling pathways within the tumor cell itself e.g. oncogenes and tumor suppres‐
sor proteins 2) Signaling pathways that regulate the tumor stromal compartment to control
angiogenesis and the immune system and 3) Elements of cancer metabolism related to the
oncogene addiction hypothesis.
Future studies will tap into these areas of basic science investigation to illuminate new avenues
for therapeutics. We hereby advocate the need to genotype and perform molecular profiling
by multi “omic” analysis on the tumor and stromal cells within the tumor and metastatic sites.
Moreover, we suggest that we should examine the adaptive responses to targeted therapeutic
agents in mouse models and patients treated with these agents in search of most potent
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combinations and mechanisms for resistance. This will be required to affect a cure of this
difficult to treat disease.
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